Maraxilibat reduces debilitating itching in children with Alagille syndrome

(Baylor College of Medicine) On behalf of Childhood Liver Disease Research Network (ChiLDReN), Texas Children's Hospital and Baylor College of Medicine researchers report that prolonged treatment with Maraxilibat resulted in clinically meaningful improvements in debilitating itching (pruritus) and related quality of life outcomes in children with Alagille syndrome. The novel pharmacological approach addresses a major unfulfilled therapeutic need to control severe and relentless itching in pediatric patients with Alagille syndrome.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news